Crossref
Incretin-based therapy for MASH: are two better than one?
Metabolism and Target Organ Damage · 17.06.2026 · 6 (2)
DOI: 10.20517/mtod.2026.74 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolism and Target Organ Damage, online erschienen am 17.06.2026. Verfasst von Richard K. Sterling. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Sterling, R. K. (2026). Incretin-based therapy for MASH: are two better than one?. Metabolism and Target Organ Damage, 6(2). https://doi.org/10.20517/mtod.2026.74
Vancouver
Sterling RK. Incretin-based therapy for MASH: are two better than one?. Metabolism and Target Organ Damage. 2026;6(2). doi:10.20517/mtod.2026.74
BibTeX
@article{Sterling2026,
author = {Sterling, Richard K.},
title = {Incretin-based therapy for MASH: are two better than one?},
journal = {Metabolism and Target Organ Damage},
year = {2026},
volume = {6},
number = {2},
doi = {10.20517/mtod.2026.74}
}
EUVIMED